文献速递银屑病与炎症性皮肤病

一种新型固定剂量卡泊三醇与二丙酸倍他米松乳膏局部治疗斑块状银屑病:2021年第30届EADV大会讨论的3期试验直接与间接证据

A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-01

本文汇总2021年第30届EADV大会的四张壁报,涉及基于Poly-Aphron分散(PAD)技术的新型固定剂量卡泊三醇/二丙酸倍他米松(CAL/BDP)乳膏。两项随机3期试验在成人斑块状银屑病中比较CAL/BDP乳膏与赋形剂及活性对照(CAL/BDP凝胶/外用混悬液),汇总数据显示乳膏在所有疗效终点上疗效更优且耐受性良好;间接比较显示乳膏在生活质量改善上相对CAL/BDP泡沫呈更佳趋势,并在五项治疗满意度维度中的四项优于泡沫。

要点

  • 两项随机3期试验汇总显示,CAL/BDP乳膏在所有疗效终点上优于CAL/BDP凝胶/外用混悬液。
  • CAL/BDP乳膏耐受性良好,与CAL/BDP凝胶/外用混悬液相当,未出现频率>1%的药物不良反应。
  • 间接比较显示CAL/BDP乳膏在生活质量改善上相对CAL/BDP泡沫呈更佳趋势,并在五项治疗满意度维度中的四项优于泡沫。

核心结论

  • CAL/BDP乳膏在两项随机3期试验汇总分析中对所有疗效终点的疗效显著优于CAL/BDP凝胶/外用混悬液,且耐受性良好、与其相当,未出现频率>1%的药物不良反应。
  • 间接比较显示,按CAL/BDP乳膏推荐8周、CAL/BDP泡沫推荐4周评估DLQI改善时,CAL/BDP乳膏相对CAL/BDP泡沫呈生活质量改善更佳的趋势。
  • CAL/BDP乳膏在五项治疗满意度维度中的四项相对CAL/BDP泡沫具有统计学优势。

研究设计与样本

  • 本文汇总2021年第30届EADV大会的四张壁报,内容基于两项随机3期试验(NCT03802344和NCT03308799)及一项间接比较。
  • 两项随机3期试验在成人斑块状银屑病患者中比较CAL/BDP乳膏与赋形剂及活性对照(CAL/BDP凝胶/外用混悬液)。
  • 间接比较采用Bucher法校正间接比较与双重差分法,比较CAL/BDP乳膏与CAL/BDP泡沫,两者均曾与CAL/BDP凝胶/外用混悬液比较。

主要发现

  • 两项试验汇总数据显示,CAL/BDP乳膏在所有疗效终点上均显著优于CAL/BDP凝胶/外用混悬液,包括PGA治疗成功、mPASI和mPASI75。
  • CAL/BDP乳膏耐受性良好,与CAL/BDP凝胶/外用混悬液相当,未出现频率>1%的药物不良反应。
  • 在NCT03308799研究中,CAL/BDP乳膏在第1、4、8周时达到峰值瘙痒数字评定量表(NRS)评分至少4分改善的受试者比例较赋形剂有大幅提高。
  • 与活性对照相比,CAL/BDP乳膏在第8周时改善了生活质量(通过皮肤病生活质量指数DLQI和EQ-VAS评估)。
  • 通过银屑病治疗便利性量表测量,CAL/BDP乳膏在所有研究时间点的治疗便利性均优于CAL/BDP凝胶/外用混悬液,包括涉及制剂油腻感和整体治疗满意度的问题。

关键数值与推荐

  • 两项随机3期试验(NCT03802344和NCT03308799)在成人斑块状银屑病中比较CAL/BDP乳膏与赋形剂及活性对照CAL/BDP凝胶/外用混悬液。
  • 汇总数据显示CAL/BDP乳膏在PGA治疗成功、mPASI和mPASI75等所有疗效终点上显著优于CAL/BDP凝胶/外用混悬液。
  • CAL/BDP乳膏未出现频率>1%的药物不良反应,耐受性与CAL/BDP凝胶/外用混悬液相当。
  • NCT03308799研究中,CAL/BDP乳膏在第1、4、8周达到峰值瘙痒NRS评分至少4分改善的受试者比例较赋形剂大幅提高。
  • 间接比较中,按CAL/BDP乳膏8周、CAL/BDP泡沫4周的推荐治疗时长评估DLQI改善,CAL/BDP乳膏相对泡沫呈更佳趋势;治疗满意度五个维度中四个维度乳膏具统计学优势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Four posters about the novel, fixed-dose calcipotriol and betamethasone dipropionate cream (CAL/BDP cream) based on Poly-Aphron Dispersion (PAD) Technology were presented at the 30th European Academy of Dermatology and Venereology (EADV) Congress 2021 and are summarized here. CAL/BDP cream was compared in two randomized, phase 3 trials to vehicle and active comparator (CAL/BDP gel/topical suspension [TS]) in adults with plaque psoriasis (NCT03802344 and NCT03308799). Pooled data from both trials demonstrated significant greater efficacy in favour of CAL/BDP cream for all efficacy endpoints, including PGA treatment success, mPASI, and mPASI75 compared to CAL/BDP gel/TS. CAL/BDP cream was well tolerated and comparable to CAL/BDP gel/TS with no adverse drug reactions with a frequency >1%. In the NCT03308799 study, CAL/BDP cream demonstrated a substantial improvement in the proportion of participants achieving a minimum 4-point improvement on the peak pruritus numeric rating scale (NRS) score compared with vehicle at Weeks 1, 4 and 8. CAL/BDP cream also improved quality of life (QoL), as assessed through the Dermatology Life Quality Index (DLQI), and the EQ-VAS at Week 8 compared with active comparator. Treatment convenience of CAL/BDP cream, as measured by the Psoriasis Treatment Convenience Scale, was superior to CAL/BDP gel/TS at all studied timepoints, including questions addressing formulation's greasiness and overall treatment satisfaction. Finally, an indirect comparison following the Bucher's method of adjusted indirect comparison and the difference-in-differences method was conducted to compare CAL/BDP cream and CAL/BDP foam, as both therapies have been compared to CAL/BDP gel/TS. Indirect evidence showed that treatment with CAL/BDP cream was associated with a trend for greater QoL improvement than CAL/BDP foam when DLQI improvement was assessed at the recommended treatment duration of 8 weeks for CAL/BDP cream and 4 weeks for CAL/BDP foam. CAL/BDP cream was statistically superior versus CAL/BDP foam in four out of five treatment satisfaction domains.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pinter A, Gold LS, Reich A, et al. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023. PMID: 36546465. doi:10.1111/jdv.18755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。